BioAge Labs, Inc. (BIOA)

NasdaqGS Currently up 0.09 (+0.95%) in today's trading session

1 member of Congress has disclosed 1 trade in BioAge Labs, Inc. (BIOA) via STOCK Act filings. The most recent disclosure was a sale by Suzan K. DelBene on 9 June 2016. Aggregate disclosed activity totals roughly $8K in sales (midpoint estimates from bracketed disclosure amounts).

BioAge Labs, Inc. is currently trading at $9.59, positioned at 23% of its 52-week range ($4.68 – $25.95).

Want to automatically copy Pelosi trades?

Mirror Nancy Pelosi's portfolio with just one click on eToro.

Copy Trading does not amount to investment advice. The value of your investments may go up or down. Your capital is at risk.

Past Performance is not an indication of future results.

Current Price
$9.59
24h Change
+0.09 (+0.95%)
52 Week Range
$4.68$25.95
View on NASDAQ

BioAge Labs, Inc. Price History and Technical Analysis

Interactive Chart

Congressional Trading Activity for BIOA

Select to highlight on chart
1 transactions
Compliance: 100%
Suzan K. DelBene9 Jun 201613 Jul 2016SaleStock$1,001 - $15,000N/A

Select transactions to view their annotations on the chart

Stock Overview

Market Data

Market Cap

$361.06M

Volume

314.85K

Beta

0.94

P/E Ratio

-4.03

Fundamentals

EPS

$-2.38

Div. Yield

-

Open

$9.39

Day Range

$9.39 – $9.76

Company Information

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ · USD
Country
US
CEO
Kristen Fortney
IPO Date
2024-09-26

BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company’s technology platform and differentiated human datasets that allows users to identify targets based on insights...

Earnings

Next Report

Q3 2026

5 Nov

EPS Est.

$-0.61

Rev. Est.

$1.5M

Days Until

59

Recent Quarters

Q2 20266 Aug
EPS$-0.58
Beat 4.5%
Q1 20268 May
EPS$-0.52
Beat 18.7%
Q4 202524 Mar
EPS$-0.72
Beat 13.3%
Q3 20256 Nov
EPS$-0.56
Beat 16.4%
Q2 20256 Aug
EPS$-0.60
Miss 7.1%
Q1 20256 May
EPS$-0.36
Beat 30.8%
Q4 202420 Mar
EPS$-1.00
Miss 72.4%
Q3 20247 Nov
EPS$-6.70
Miss 830.6%
Q2 202426 Sept
EPS$-0.60
Q4 202331 Mar
EPS$-1.74
Q3 202331 Dec
EPS$-2.81
Q2 202330 Sept
EPS$-1.96
Q1 202330 Jun
EPS$-2.30
Q4 202231 Mar
EPS$-1.48
Q4 201727 Mar
EPS-

No dividend data available for this stock.

No stock split data available for this stock.

Similar Stocks

Based on congressional trading patterns

Smart Recommendations
No similar stocks found
No congressional trading patterns available for recommendations

Frequently Asked Questions about BIOA

Which members of Congress have traded BIOA?
1 member of Congress has disclosed 1 trade in BioAge Labs, Inc. (BIOA) under the STOCK Act: Suzan K. DelBene.
When was BIOA most recently disclosed by Congress?
The most recent BIOA disclosure was a sale by Suzan K. DelBene on 9 June 2016.
What is the total disclosed congressional trading volume for BIOA?
Members of Congress have disclosed approximately $8K in BIOA sales (midpoint estimate derived from the bracketed amount ranges used in STOCK Act filings).
How can I track new congressional trades in BIOA?
This BIOA page updates as soon as new STOCK Act disclosures are filed for BioAge Labs, Inc.. Every trade, politician, transaction date and amount range is surfaced above, typically within hours of the official filing appearing on the House or Senate disclosure portals.
Pelosi Tracker
© 2026 - All rights reserved. Powered by Vantara Labs
Pelosi Tracker is an independent, third-party platform. It is not affiliated with, endorsed by, or in any way associated with Nancy Pelosi, her office or her representatives, or with any other member of Congress. Any use of her name is solely for the purpose of discussing publicly available information.The information provided by Pelosi Tracker is for informational and educational purposes only and is not intended to serve as, nor should it be construed as, financial or investment advice. The data presented here is sourced from publicly available filings and records. While we strive for accuracy, timeliness, and completeness, we do not guarantee that all information is error-free or current.